Lebrikizumab ADvocate1 and 2 Monotherapy and ADjoin (Long-Term) Trials: Use of Topicals Therapies.

Stein-Gold L, DeBruin-Weller M, Thaci D, Kircik L, Yang C, Rueda MJ, Gallo G, Paller A

Open source

DOI
10.1007/s13555-026-01771-5
Published
2026 Jun
Container
Dermatology and therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s13555-026-01771-5,
  title = {Lebrikizumab ADvocate1 and 2 Monotherapy and ADjoin (Long-Term) Trials: Use of Topicals Therapies.},
  author = {Stein-Gold L and DeBruin-Weller M and Thaci D and Kircik L and Yang C and Rueda MJ and Gallo G and Paller A},
  year = {2026},
  journal = {Dermatology and therapy},
  doi = {10.1007/s13555-026-01771-5},
  url = {https://doi.org/10.1007/s13555-026-01771-5}
}

RIS

TY  - JOUR
TI  - Lebrikizumab ADvocate1 and 2 Monotherapy and ADjoin (Long-Term) Trials: Use of Topicals Therapies.
AU  - Stein-Gold L
AU  - DeBruin-Weller M
AU  - Thaci D
AU  - Kircik L
AU  - Yang C
AU  - Rueda MJ
AU  - Gallo G
AU  - Paller A
PY  - 2026
JO  - Dermatology and therapy
DO  - 10.1007/s13555-026-01771-5
UR  - https://doi.org/10.1007/s13555-026-01771-5
ER  - 

APA

L, S., M, D., D, T., L, K., C, Y., MJ, R., G, G., & A, P. (2026). Lebrikizumab ADvocate1 and 2 Monotherapy and ADjoin (Long-Term) Trials: Use of Topicals Therapies.. Dermatology and therapy. https://doi.org/10.1007/s13555-026-01771-5

Source records